Cwm LLC Buys 3,272 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cwm LLC raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 93.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,764 shares of the biopharmaceutical company’s stock after buying an additional 3,272 shares during the quarter. Cwm LLC’s holdings in Alnylam Pharmaceuticals were worth $1,860,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in ALNY. Vanguard Group Inc. boosted its stake in Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after purchasing an additional 287,064 shares in the last quarter. Quattro Financial Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after buying an additional 4,809 shares during the last quarter. Plato Investment Management Ltd increased its position in shares of Alnylam Pharmaceuticals by 2,666.3% during the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after acquiring an additional 4,346 shares in the last quarter. SteelPeak Wealth LLC raised its holdings in Alnylam Pharmaceuticals by 147.7% in the 1st quarter. SteelPeak Wealth LLC now owns 6,860 shares of the biopharmaceutical company’s stock worth $1,025,000 after acquiring an additional 4,090 shares during the last quarter. Finally, Diversified Trust Co bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $1,210,000. 92.97% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares of the company’s stock, valued at approximately $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,398 shares of company stock worth $13,595,460 over the last quarter. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $287.36 on Wednesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $289.67. The company has a market capitalization of $36.35 billion, a P/E ratio of -107.22 and a beta of 0.39. The company has a fifty day moving average of $269.96 and a 200 day moving average of $214.43.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The business’s revenue was up 107.0% on a year-over-year basis. During the same period last year, the company earned ($2.21) EPS. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ALNY. Needham & Company LLC restated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 10th. Bank of America boosted their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday. Citigroup raised their price target on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 10th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. Six investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $285.95.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.